Full-Time

Principal Investigator

Updated on 9/3/2026

Celerion

Celerion

1,001-5,000 employees

Global CRO for early-phase development

No salary listed

Lincoln, NE, USA

In Person

MD

Category
Medical, Clinical & Veterinary (1)
Required Skills
Ruby

Get referred to Celerion

See people who can refer or advise you

Requirements
  • MD or DO degree and current state license
  • Basic Life Support and Advanced Cardiac Life Support certification
  • Successful completion of an ACGME residency program in family medicine, internal medicine, or emergency medicine
  • Hold a DEA certificate for schedule II medications
Responsibilities
  • Review protocol and Investigator Brochure for subject safety, scientific, and operational feasibility of study. Provide input to sponsor as indicated.
  • Complete FDA 1572 and financial disclosure forms.
  • Attend study initiation meetings with sponsor.
  • Communicate with Institutional Review Board during protocol approval process and subject safety issues.
  • Explain study to subject and answer questions, ensure proper consent, and perform screening examination.
  • Final review of all screening data and authorization of subjects to be enrolled in the study.
  • Perform scheduled per protocol, and unscheduled per adverse event, physicals during study conduct.
  • Manage adverse events/clinical evaluation of subjects and determine adverse event relationship to investigational product, severity, and etiology.
  • Review pre-dose lab work, ECGs, and other study data and determine appropriate action plan based on these results.
  • Review safety data with sponsor.
  • Compose SAE and other reporting documents as indicated.
  • Review and sign Case Report Forms and final Clinical Study Reports.
  • Review all serious adverse events and SUSARs to the Sponsor and IRB within statutory timelines.
  • Data review of all end-of-study data to determine if re-checks are necessary.
  • Safety-monitoring – perform end-of-study physical exams and follow-up ongoing adverse events.
  • Case Report Forms review – review and sign all case report forms at end of study.
  • Assist in on-site client review of case report forms.
  • Assist with identifying and maintaining a network of physician specialists to contract on studies.
  • Present Celerion’s capabilities and experience during sponsor meetings and events.
  • Assist in the design of study and time/event schedules involving special medical procedures.
  • Function as a medical/clinical informational resource for the site.
  • Assist other departments with development of SOPs, training plans, etc.
  • Facilitate emergency response training and review of clinical safety procedures.
Desired Qualifications
  • 3-5 years of medical/clinical experience preferred
  • Clinical research experience preferred

Celerion is a global contract research organization focused on early-phase drug development. It supports pharmaceutical and biotech clients with trial design, feasibility, project management, clinical and medical monitoring, bioanalytical sciences, and regulatory affairs, all conducted under contract. Its work hinges on metabolite profiling using high-resolution mass spectrometry to inform development decisions. With 40+ years of experience and a global, integrated service network, Celerion aims to help clients bring safe, effective treatments to patients faster by delivering rigorous, timely research.

Company Size

1,001-5,000

Company Stage

Acquired

Total Funding

N/A

Headquarters

Lincoln, Nebraska

Founded

2010

Get referred to Celerion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • THL bought Celerion for $1.8 billion in June 2026, validating demand.
  • Zurich lab expansion in June 2026 added capacity for rising bioanalytical demand.
  • Labnotes 2025 improved reporting and database workflows, strengthening sponsor-facing productivity.

What critics are saying

  • Private-equity ownership after THL's June 2026 closing demands aggressive EBITDA growth and exits.
  • Large CROs like IQVIA and Labcorp can undercut pricing in Phase 1 and bioanalysis.
  • A quality failure in CLIA/CAP-regulated labs would damage trust and halt studies.

What makes Celerion unique

  • Celerion combines Phase 1 clinics with bioanalytical labs across Nebraska, Phoenix, Zurich, and Belfast.
  • Its Zurich and Lincoln labs specialize in metabolite profiling, pharmacokinetics, immunogenicity, and gene-therapy analytics.
  • Labnotes and integrated sample handling speed sponsor decisions across complex early-development programs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

4%
Swisstrade
Jun 30th, 2026
Celerion invests in its site in Fehraltdorf.

Celerion invests in its site in Fehraltdorf. 30 June 2026 10:05 Supporting partner. Fehraltdorf/Lincoln - Celerion is expanding its lab in Fehraltdorf. In so doing, the company, which is headquartered in the US State of Nebraska, is seeking to respond to increasing global demand for bioanalytical services. The company's Swiss lab supports Celerion's research activities in the UK and USA. (CONNECT) Celerion is expanding its bioanalytical laboratory at the company's Swiss location in Fehraltdorf near to Zurich. As detailed in a statement issued by the company from Lincoln in the US State of Nebraska, this investment will strengthen Celerion's ability to meet the growing worldwide demand for bioanalytical services, in addition to supporting rapid study execution and providing access to specialized scientific expertise across complex drug development programs. The plans involve targeted investments in cutting-edge instrumentation and specialized scientific talent. "This expansion reflects both the growth of the bioanalytical market and the increasing demand we are seeing from our clients worldwide", as Chad Briscoe, Executive Vice President of Global Bioanalytical Services at Celerion, explains in the statement. Celerion's Swiss laboratory is integrated with the clinical research units in the USA and the UK, which is said to facilitate efficient sample management and the rapid delivery of high-quality data. "As therapeutic modalities continue to evolve, our clients need bioanalytical partners that can scale alongside increasingly complex development programs", comments Susan Thornton, who founded Celerion in 2010 and has been leading the company as CEO since then. "This investment ensures we remain well-positioned to deliver the expertise, quality, and responsiveness that help accelerate the development of new medicines". ce/mm

Celerion
Jun 25th, 2026
Celerion expands Zurich bioanalytical laboratory to meet growing market demand.

Celerion expands Zurich bioanalytical laboratory to meet growing market demand. LINCOLN, Neb.; June 25, 2026 - Celerion, a global leader in early clinical research and bioanalytical services, today announced the expansion of its bioanalytical laboratory in Zurich, Switzerland. The investment strengthens Celerion's ability to support increasing global demand for bioanalytical services, providing clients with enhanced capacity, rapid study execution, and access to specialized scientific expertise across complex drug development programs. "This expansion reflects both the growth of the bioanalytical market and the increasing demand we are seeing from our clients worldwide," said Chad Briscoe Ph.D., Executive Vice President of Global Bioanalytical Services at Celerion. "By investing in both our people and technology, we are expanding our ability to deliver fast, actionable data while maintaining the scientific rigor and quality that are fundamental to successful drug development." The Zurich laboratory offers a comprehensive range of bioanalytical capabilities, including pharmacokinetic analysis, immunogenicity testing, biomarker assays, biosimilar support, gene therapy analytics, and metabolite profiling. Integrated with Celerion's clinical research units in the United States and United Kingdom, the laboratory enables efficient sample management and rapid delivery of high-quality data to support critical development decisions. The expansion includes targeted investments in advanced instrumentation and specialized scientific talent, increasing operational capacity while maintaining the high standards of quality, accuracy, and responsiveness that clients expect from Celerion. Located in one of Europe's leading life sciences hubs, the Zurich facility serves as a key component of the company's global bioanalytical network. Susan Thornton, Ph.D., Chief Executive Officer of Celerion, added, "As therapeutic modalities continue to evolve, our clients need bioanalytical partners that can scale alongside increasingly complex development programs. This investment ensures we remain well-positioned to deliver the expertise, quality, and responsiveness that help accelerate the development of new medicines." The expanded Zurich laboratory is fully operational and actively supporting new and ongoing clinical and bioanalytical programs, reinforcing Celerion's commitment to advancing drug development through scientific excellence and global collaboration. About Celerion Celerion, a global leader in early clinical research, offers clients expert-driven services that enable fast, informed decisions in drug development. With over 50 years of experience, Celerion specializes in Phase 1 studies, including first-in-human dose escalation, drug-drug interactions, cardiac safety, bioequivalence, metabolism, and pharmacokinetics in patient populations. Celerion also provides comprehensive data management, biostatistics, clinical monitoring, and bioanalytical services. For more information, visit www.celerion.com.

Legal Desire
Jun 15th, 2026
THL Partners takes majority stake in clinical pharmacology leader Celerion

Celerion, a global clinical pharmacology and bioanalytical sciences company, has received a majority investment from private equity firm THL Partners. The deal will support Celerion's expansion of its clinical and bioanalytical capabilities. The investment aims to help Celerion continue its growth and innovation whilst advancing its work with pharmaceutical and biotechnology partners to bring new therapies to patients worldwide. Financial terms of the transaction were not disclosed. THL Partners specialises in middle-market growth companies.

PR Newswire
Apr 22nd, 2026
H.I.G. Capital sells clinical research firm Celerion to THL Partners

H.I.G. Capital has signed a definitive agreement to sell Celerion Holdings, a global contract research organisation specialising in clinical pharmacology and bioanalytical sciences, to funds affiliated with THL Partners. Financial terms were not disclosed. Headquartered in Lincoln, Nebraska, Celerion provides clinical pharmacology services including first-in-human dose escalation, cardiac safety studies and drug-drug interaction research. The company operates facilities in Lincoln, Phoenix, Zurich and Belfast, serving pharmaceutical and biotechnology clients. H.I.G. acquired Celerion in November 2022 and supported strategic investments across commercial, operational and technology initiatives, including expanding the company's clinical and laboratory footprint. BofA Securities and Lazard Frères served as financial advisers to H.I.G. and Celerion on the transaction.

PharmiWeb
May 7th, 2025
Celerion Launches Enhanced Version Of Labnotes Bioanalytical Data Management Software

LINCOLN, Neb.; May 6, 2025 (Business Wire) – Celerion, a global leader in early clinical research and bioanalytical services, announced the launch of the latest version of Labnotes, its cutting-edge bioanalytical electronic laboratory notebook software elevating data handling and analysis capabilities for sponsors. The latest system enhancements streamline laboratory documentation and improve operational efficiency for users. The updated platform also offers advanced tools for handling and organizing large datasets, ensuring faster processing of reports and optimized database queries